Toronto Dominion Bank
SRPT icon

Toronto Dominion Bank’s Sarepta Therapeutics SRPT Stock Holding History

Toronto Dominion Bank’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-30,000
Closed -$611K – 1073
2013
Q4 		$611K Buy
+30,000
New +$891K ﹤0.01% 419

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Toronto Dominion Bank's SRPT Position: Q4 2025 in Review

Toronto Dominion Bank sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 17 shares — an estimated $330 sold.

Toronto Dominion Bank first reported a position in SRPT in Q3 2019 and held it in 10 quarters. The position peaked at $13.4M in Q4 2021. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Toronto Dominion Bank reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Toronto Dominion Bank sold 17 Sarepta Therapeutics shares in Q4 2025, an estimated $330.
  • Toronto Dominion Bank first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 10 quarters.
  • Toronto Dominion Bank's Sarepta Therapeutics position peaked at $13.4M in Q4 2021.
  • 346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Toronto Dominion Bank's 13F filing for Q4 2025, filed 17 Feb 2026.